These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 6327714)
1. Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation. Innerarity TL; Weisgraber KH; Arnold KS; Rall SC; Mahley RW J Biol Chem; 1984 Jun; 259(11):7261-7. PubMed ID: 6327714 [TBL] [Abstract][Full Text] [Related]
2. Defective hepatic lipoprotein receptor binding of beta-very low density lipoproteins from type III hyperlipoproteinemic patients. Importance of apolipoprotein E. Hui DY; Innerarity TL; Mahley RW J Biol Chem; 1984 Jan; 259(2):860-9. PubMed ID: 6319389 [TBL] [Abstract][Full Text] [Related]
3. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Rall SC; Weisgraber KH; Innerarity TL; Mahley RW Proc Natl Acad Sci U S A; 1982 Aug; 79(15):4696-700. PubMed ID: 6289314 [TBL] [Abstract][Full Text] [Related]
4. Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. Rall SC; Weisgraber KH; Innerarity TL; Bersot TP; Mahley RW; Blum CB J Clin Invest; 1983 Oct; 72(4):1288-97. PubMed ID: 6313758 [TBL] [Abstract][Full Text] [Related]
5. The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. Innerarity TL; Friedlander EJ; Rall SC; Weisgraber KH; Mahley RW J Biol Chem; 1983 Oct; 258(20):12341-7. PubMed ID: 6313652 [TBL] [Abstract][Full Text] [Related]
6. Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia. Rall SC; Weisgraber KH; Innerarity TL; Mahley RW J Clin Invest; 1983 Apr; 71(4):1023-31. PubMed ID: 6300187 [TBL] [Abstract][Full Text] [Related]
7. A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein E1. Weisgraber KH; Rall SC; Innerarity TL; Mahley RW; Kuusi T; Ehnholm C J Clin Invest; 1984 Apr; 73(4):1024-33. PubMed ID: 6323533 [TBL] [Abstract][Full Text] [Related]
8. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Matsunaga A; Sasaki J; Komatsu T; Kanatsu K; Tsuji E; Moriyama K; Koga T; Arakawa K; Oikawa S; Saito T; Kita T; Doi T Kidney Int; 1999 Aug; 56(2):421-7. PubMed ID: 10432380 [TBL] [Abstract][Full Text] [Related]
9. The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-Leiden: role in receptor-binding activity. Dong LM; Innerarity TL; Arnold KS; Newhouse YM; Weisgraber KH J Lipid Res; 1998 Jun; 39(6):1173-80. PubMed ID: 9643348 [TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. Weisgraber KH J Lipid Res; 1990 Aug; 31(8):1503-11. PubMed ID: 2280190 [TBL] [Abstract][Full Text] [Related]
11. Binding of apolipoprotein A-I and A-II after recombination with phospholipid vesicles to the high density lipoprotein receptor of luteinized rat ovary. Hwang J; Menon KM J Biol Chem; 1985 May; 260(9):5660-8. PubMed ID: 2985608 [TBL] [Abstract][Full Text] [Related]
12. Binding of chylomicron remnants and beta-very low density lipoproteins to hepatic and extrahepatic lipoprotein receptors. A process independent of apolipoprotein B48. Hui DY; Innerarity TL; Milne RW; Marcel YL; Mahley RW J Biol Chem; 1984 Dec; 259(24):15060-8. PubMed ID: 6096356 [TBL] [Abstract][Full Text] [Related]
13. The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. Weisgraber KH; Innerarity TL; Harder KJ; Mahley RW; Milne RW; Marcel YL; Sparrow JT J Biol Chem; 1983 Oct; 258(20):12348-54. PubMed ID: 6313653 [TBL] [Abstract][Full Text] [Related]
14. In vivo alteration of a mutant human protein using the free thiol cysteamine. Gahl WA; Gregg RE; Hoeg JM; Fisher E Am J Med Genet; 1985 Feb; 20(2):409-17. PubMed ID: 3976729 [TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia. Havekes L; de Wit E; Leuven JG; Klasen E; Utermann G; Weber W; Beisiegel U Hum Genet; 1986 Jun; 73(2):157-63. PubMed ID: 3721502 [TBL] [Abstract][Full Text] [Related]
16. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. Horie Y; Fazio S; Westerlund JR; Weisgraber KH; Rall SC J Biol Chem; 1992 Jan; 267(3):1962-8. PubMed ID: 1730728 [TBL] [Abstract][Full Text] [Related]
17. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. Dong LM; Wilson C; Wardell MR; Simmons T; Mahley RW; Weisgraber KH; Agard DA J Biol Chem; 1994 Sep; 269(35):22358-65. PubMed ID: 8071364 [TBL] [Abstract][Full Text] [Related]
18. A hepatocyte receptor for high-density lipoproteins specific for apolipoprotein A-I. Rifici VA; Eder HA J Biol Chem; 1984 Nov; 259(22):13814-8. PubMed ID: 6094531 [TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E2(Arg158----Cys) frequency in a hyperlipidemic French-Canadian population of apolipoprotein E2/2 subjects. Determination by synthetic oligonucleotide probes. Weisgraber KH; Newhouse YM; Taylor JM; Tuan B; Nestruck AC; Davignon J; Mahley RW Arteriosclerosis; 1989; 9(1):50-7. PubMed ID: 2912421 [TBL] [Abstract][Full Text] [Related]
20. Mechanism of dissociation of human apolipoproteins A-I, A-11, and C from complexes with dimyristoylphosphatidylcholine as studied by thermal denaturation. Reijngoud DJ; Phillips MC Biochemistry; 1984 Feb; 23(4):726-34. PubMed ID: 20815113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]